Two neoadjuvant immunotherapy combinations for head and neck cancer substantially increased the response rate versus a single drug, a small randomized trial showed. The pathologic tumor response ...

The Australian cancer-treatment company said Monday the median rate for overall survival was 17.6 months for patients taking a combination of eftilagimod alfa and Merck's pembrolizumab drug Keytruda.

Low dental health-related quality of life (HRQoL) at the time of head and neck cancer diagnosis may be associated with worse survival outcomes. This research was published in mid-November in BMC Oral ...

Key Takeaways Nivolumab with cisplatin and radiotherapy improved 3-year disease-free survival to 63.1% versus 52.5% in high-risk head and neck cancer patients. The trial enrolled 680 patients, with ...

Merus reports promising interim data for petosemtamab in head and neck cancer, showing 63% response rate and 79% survival at 12 months. Quiver AI Summary Merus N.V. announced promising interim ...

Biotech ASCO: Bicara ties antibody to 46% 2-year survival rate for head and neck cancer subset By Gabrielle Masson Jun 1, 2025 3:36pm Bicara Therapeutics ASCO 2025 Merus ASCO ...

Patients with locally advanced head and neck cancer who received the immune checkpoint inhibitor pembrolizumab before, during and after standard-of-care surgery had longer event-free survival ...

Neoadjuvant chemotherapy followed by transoral robotic surgery (NECTORS) and neck dissection led to better survival outcomes in HPV-related oropharyngeal squamous cell carcinoma.

Patients with locally advanced head and neck cancer who received the immune checkpoint inhibitor pembrolizumab before, during and after standard-of-care surgery had longer event-free survival ...